tbuckley/cabot-search huggingface dataset:
Challenges in Oncology
Authors: Pia Raanani, John M. Goldman, Isaac Ben-Bassat
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.3.869 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11821474 Challenges in Oncology Case 3. Depigmentation in a Chronic Myeloid Leukemia Patient Treated With STI-571 Pia RaananixPia RaananiSearch for articles by this author , John M. GoldmanxJohn M. GoldmanSearch for articles by this author , Isaac Ben-BassatxIsaac Ben-BassatSearch for articles by this author Show More The Chaim Sheba Medical Center, Tel-Hashomer, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; and Hammersmith Hospital and Imperial College School of Medicine, London, United Kingdom https://doi.org/10.1200/JCO.2002.20.3.869 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians
Authors: Amir Qaseem, Russell P. Harris, Mary Ann Forciea
Journal: Annals of Internal Medicine (2016)

Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of gout. Methods: Using the ACP grading system, the committee based these recommendations on a systematic review of randomized, controlled trials; systematic reviews; and large observational studies published between January 2010 and March 2016. Clinical outcomes evaluated included pain, joint swelling and tenderness, activities of daily living, patient global assessment, recurrence, intermediate outcomes of serum urate levels, and harms. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with acute or recurrent gout. Recommendation 1: ACP recommends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout. (Grade: strong recommendation, high-quality evidence) Recommendation 2: ACP recommends that clinicians use low-dose colchicine when using colchicine to treat acute gout. (Grade: strong recommendation, moderate-quality evidence) Recommendation 3: ACP recommends against initiating long-term urate-lowering therapy in most patients after a first gout attack or in patients with infrequent attacks. (Grade: strong recommendation, moderate-quality evidence) Recommendation 4: ACP recommends that clinicians discuss benefits, harms, costs, and individual preferences with patients before initiating urate-lowering therapy, including concomitant prophylaxis, in patients with recurrent gout attacks. (Grade: strong recommendation, moderate-quality evidence)
Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2–&lt;6 Years At Enrollment.
Authors: Elliott Vichinsky, Amal El-Beshlawy, Azzam Alzoebie, Francoise Bernaudin, Suzanne Koussa, Thirachit Chotsampancharoen, Ali El-Ali, Caroline Arrowsmith, Nicolas Martin, Mohsen El-Alfy
Journal: Blood (2012)
Functional and Familial Risk of B Lineage Malignancies in Patients Carrying Single Nucleotide Polymorphisms (SNPs) in the Hyaluronan Synthase 1 Gene (HAS1),
Authors: Linda M. Pilarski, Hemalatha Kuppusamy, Jitra Kriangkum, Amanda Warkentin, Sunita Ghosh, Spencer B Gibson, Hlif Steingrimsdottir, Vilhelmina Haraldsdottir, James B Johnston, Helga M Ogmundsdottir, Andrew R Belch
Journal: Blood (2011)
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease
Authors: Vivan J.M. Baggen, Annemien E. van den Bosch, Jannet A. Eindhoven, Anne-Rose W. Schut, Judith A.A.E. Cuypers, Maarten Witsenburg, Monique de Waart, Ron H.N. van Schaik, Felix Zijlstra, Eric Boersma, Jolien W. Roos-Hesselink
Journal: Circulation (2016)

The number of patients with adult congenital heart disease (ACHD) is rapidly increasing. To optimize patient management, there is a great need to accurately identify high-risk patients. Still, no biomarker has been firmly established as a clinically useful prognostic tool in this group. We studied the association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive troponin-T, and growth-differentiation factor 15 with cardiovascular events in ACHD.Clinically stable patients with ACHD who routinely visited the outpatient clinic between April 2011 and April 2013 underwent clinical assessment, electrocardiography, echocardiography, and biomarker measurement (NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15) at the time of study inclusion. Patients were prospectively followed for the occurrence of cardiovascular events (death, heart failure, hospitalization, arrhythmia, thromboembolic events, and reintervention). Survival curves were derived by the Kaplan-Meier method, and Cox regression was performed to investigate the relation between biomarkers and events with adjustment for multiple clinical and echocardiographic variables.In total, 595 patients were included (median age, 33 years; interquartile range, 25-41 years; 58% male; 90% New York Heart Association class I). Patients were followed during a median of 42 (interquartile range, 37-46) months. Of the 3 evaluated biomarkers, NT-proBNP in the upper quartile (>33.3 pmol/L) was most strongly associated with cardiovascular events (n=165, adjusted hazard ratio, 9.05 [3.24-25.3], P<0.001) and with death or heart failure (n=50, adjusted hazard ratio, 16.0 [2.04-126], P<0.001). When NT-proBNP was analyzed as a continuous variable, similar findings were retrieved. The cumulative proportion of patients with death and heart failure was only 1% in the lowest 2 NT-proBNP quartiles. Elevated NT-proBNP (>14 pmol/L), elevated high-sensitive troponin-T (>14 ng/L), and elevated growth-differentiation factor 15 (>1109 ng/L) identified those patients at highest risk of cardiovascular events (log-rank P<0.0001).NT-proBNP provides prognostic information beyond a conventional risk marker model in patients with ACHD and can reliably exclude the risk of death and heart failure. Elevated levels of NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15 identify patients at highest risk of cardiovascular events. These biomarkers therefore may play an important role in the monitoring and management of patients with ACHD.
Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)
Authors: Ali T Taher, John B Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Dany Habr, Jacqueline Ros, Zewen Zhu, M Domenica Cappellini
Journal: Blood (2012)
Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)
Authors: Justine Decroocq, Raphael Itzykson, Stéphane Vigouroux, Mauricette Michallet, Ibrahim Yakoub-Agha, Florence Beckerich, Anne Huynh, Felipe Suarez, Patrice Chevallier, Stephanie Nguyen quoc, Bruno Lioure, Laurence Clément, Nathalie Fegueux, Nathalie Contentin, Gaelle Guillerm, Jérôme Cornillon, Martin Carré, Natacha Maillard, Mélanie Mercier, Mohamad Mohty, Yves Beguin, Jean-Henri Bourhis, Amandine Charbonnier, Charlotte Jubert, Charles Dauriac, Jacques-Olivier Bay, Didier Blaise, Eric Deconinck, Nicole Raus, Regis Peffault de la Tour, Nathalie Dhedin
Journal: Blood (2015)
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy
Authors: Kendra L. Sweet, Najla H Al Ali, Jeffrey E Lancet, Ben Creelan, Sara Tinsley, Bijal D. Shah, Ling Zhang, Rami S. Komrokji, Javier Pinilla-Ibarz
Journal: Blood (2012)
SEDENTARY BEHAVIOUR – ARE WE SITTING TOO MUCH?
Authors: O Ikogho
Journal: British Journal of Sports Medicine (2016)

Sedentary behavior is defined as “Engaging in behaviors during the waking day that are done while sitting or reclining and result in little energy expenditure.” (Koster et al Diabetes Care, 2011;34(2):497–503) Research shows that there are health risks are associated with spending more than 6–7 sedentary hours per day, independent of exercise time. (Patel et al, Am J Epidemiol, 2010;172(4):419–29) The aim was to identify which patients could benefit from reducing their sedentary time. 101 patients at Cleadon Park Medical Centre, South Shields were questioned. Sedentary hours were self-reported, physical activity was measured using The General Practice Physical Activity Questionnaire (GPPAQ). Four categories emerged: Less than active and excessively sedentary n= 45 (45%); Less than active and not excessively sedentary n= 37 (37%); Active and excessively sedentary n=9 (9%); Active and not excessively sedentary n=10 (10%). This shows patients are not exercising enough, sitting too much or, as with 45%, both. Reducing sedentary time as well as increasing physical activity should be encouraged. Many patients, including those who are already adequately active, would benefit.
Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group Study.
Authors: Huining Kang, Edward J. Bedrick, I-Ming Chen, Carla S. Wilson, Susan R. Atlas, Richard C. Harvey, Stephen P. Hunger, Meenakshi Devidas, Michael J. Borowitz, Paul Bowman, William L. Carroll, Bruce Camitta, Gregory H. Reaman, Cheryl L. Willman
Journal: Blood (2007)
Sixty seconds on . . .<i>Wolbachia</i>
Authors: Susan Mayor
Journal: BMJ (2016)

Wolbachia is a genus of bacteria that occurs in 60% of insects worldwide. You may never have heard of it before, but it’s the commonest parasitic microbe in the world. The reason it’s of particular interest at the moment is that Wolbachia species significantly reduce the ability of mosquitoes to replicate viruses such as Zika and …
KNEE LAXITY MEASUREMENT IN ACUTE KNEE TRAUMA AND ACL EVALUATION WITH THE ROLIMETER
Authors: D Ericsson, A Hafsteinsson Östenberg, M Alricsson
Journal: British Journal of Sports Medicine (2016)

The Rolimeter is an instrument that quantifies anterior knee laxity and has in previous studies showed satisfactory results regarding intra- and inter test reliability in subjects without injuries or with chronic ACL deficiency. The aim of the present study was to test reliability of the Rolimeter in the acute phase following a substantial knee trauma. The repeatability of the test procedure was also investigated. Totally 15 subjects (aged 22.7±6.9) with acute knee trauma were examined by one single observer at three different times with the Rolimeter (arthrometer model, Aircast, Europa) using maximum force. Both injured and non-injured knees were examined and anterior posterior displacement was recorded. Endpoint examination was used as “golden standard” in data analysis. The results showed strong significant correlations for the Rolimeter scores of knee laxity between baseline and endpoint for both injured and non-injured knees (r=0.928, p&lt;0.01 and r=0.987, p&lt;0.01 respectively). Mean differences in anterior laxity were small with no significant differences between readings. High repeatability was found in repeated measurements with no significant change over time for the non-injured knees. The study implicates that the Rolimeter produces reliable quantification of anterior knee laxity in repeated measurements even in the acute phase following knee trauma. In combination with manual tests the Rolimeter seems to be a valuable instrument in diagnosing ACL injuries.
Combination Therapy Based on Bortezomib for Newly-Diagnosed Multiple Myeloma: a Chinese Experience
Authors: Li Yang, Jing-Song He, WenJun Wu, Xiujin Ye, Jimin Shi, Jie Zhang, Wanzhuo Xie, Xiaoyan Han, Gaofeng Zheng, Guoqing Wei, Li Li, Jingjing Zhu, Xiaoli Zhu, Weijia Huang, Xiaojian Meng, He Huang, Maofang Lin, Zhen Cai
Journal: Blood (2010)
Loss of the Methyl-CpG–Binding Protein ZBTB4 Alters Mitotic Checkpoint, Increases Aneuploidy, and Promotes Tumorigenesis
Authors: Audrey Roussel-Gervais, Ikrame Naciri, Olivier Kirsh, Laetitia Kasprzyk, Guillaume Velasco, Giacomo Grillo, Pierre Dubus, Pierre-Antoine Defossez
Journal: Cancer Research (2016)

Abstract Chromosome segregation during mitosis is monitored by the mitotic checkpoint and is dependent upon DNA methylation. ZBTB4 is a mammalian epigenetic regulator with high affinity for methylated CpGs that localizes at pericentromeric heterochromatin and is frequently downregulated in cancer. Here, we report that decreased ZBTB4 expression correlates with high genome instability across many frequent human cancers. In human cell lines, ZBTB4 depletion was sufficient to increase the prevalence of micronuclei and binucleated cells in parallel with aberrant mitotic checkpoint gene expression, a weakened mitotic checkpoint, and an increased frequency of lagging chromosomes during mitosis. To extend these findings, we generated Zbtb4-deficient mice. Zbtb4−/− mice were smaller than their wild-type littermates. Primary cells isolated from Zbtb4−/− mice exhibited diminished mitotic checkpoint activity, increased mitotic defects, aneuploid cells marked by a specific transcriptional signature, and increased genomic instability. Zbtb4−/− mice were also more susceptible to 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA)–induced skin carcinogenesis. Our results establish the epigenetic regulator ZBTB4 as an essential component in maintaining genomic stability in mammals. Cancer Res; 77(1); 62–73. ©2016 AACR.
Cytokine Profiling of ABC-Subtype and GCB-Subtype Diffuse Large B Cell Lymphoma: Systemic Nfkb Activation and Impact on Myeloid-Derived Suppressor Cells Distribution
Authors: David Foureau, Lawrence J Druhan, Nury M Steuerwald, Sarah A Baxter, Omotayo O. Fasan, Belinda R Avalos, Nilanjan Ghosh
Journal: Blood (2015)
High Levels of Nm23-H2 Protein Are a Specific and Invariable Feature of CML-CP Cells Due to Post Transcriptional Control Via a Bcr-Abl Dependent Pathway
Authors: Sabine Tschiedel, Michael Cross, Enrica Müller, Annette Jilo, Song-Yau Wang, Vladan ucinic, Thoralf Lange, Haifa Kathrin Al-Ali, Dietger W Niederwieser
Journal: Blood (2010)
MPTH-09MOLECULAR MARKERS AND THEIR PROGNOSTIC IMPACT IN PEDIATRIC EPENDYMOMAS
Authors: Asuka Araki, Jozsef Virag, Johannes Gojo, Monika Chocholous, Andras Kiss, Gábor Lotz, Zsuzsa Schaff, Miklos Garami, Manila Antonelli, Irene Slavc, Thomas Czech, Balazs Hegedus, Christine Haberler
Journal: Neuro-Oncology (2015)

BACKGROUND: Ependymomas are the third most common CNS tumors in children. To date, extent of resection and patient age are the most important prognostic factors. To refine treatment strategies and improve patient outcome molecular markers are needed. Recently, the prognostic impact of tenascin-C (TNC) expression and gain of chromosome 1q have been described. Additionally, different molecular subgroups in supra-, infratentorial and spinal ependymomas have been identified including two subgroups characterized by RELA and YAP1 fusion genes in supratentorial cases. METHODS: We have analyzed a series of 75 pediatric ependymomas including 52 infra- and 23 supratentorial tumors. Patient age ranged between 0.9 and 21 years. FFPE sections were analysed using 1q25/1p36 FISH probes and antibodies against TNC, LAMA2, NF-κB, L1CAM and claudin-5. Immunohistochemical expression of LAMA2, NF-κB, L1CAM and claudin-5 was analyzed in additional 12 supratentorial ependymomas. RESULTS: 1q gain was found in 16%, TNC and Lama2 expression in 67% and 34%, respectively. Gain of 1q and TNC expression were predominantly detectable in infratentorial, whereas claudin-5 was almost exclusively expressed in supratentorial tumors. Claudin5, NF-κB and L1CAM expression was present in 68.6%, 48.6%, and 68.6% of all 35 supratentorial tumors, and a significant correlation between these markers was found. In two tumors with claudin5 and L1CAM expression RT-PCR verified the presence of a RELA fusion, thus confirming claudin5 and L1CAM as markers for tumors with RELA fusion. Patients with 1q gain and TNC expression had a significantly shorter overall survival, whereas no prognostic impact for LAMA2 and claudin5/L1CAM/ NF-κB was found. CONCLUSIONS: We confirm the prognostic impact of 1q gain and TNC expression in pediatric ependymomas and show that supratentorial ependymomas with RELA fusion can be recognized by L1CAM/claudin-5 expression. Nevertheless, there was no significant difference in outcome between supratentorial tumors with and without RELA fusion.
GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease
Authors: Josh Lehrer-Graiwer, Jo Howard, Claire Jane Hemmaway, Moji Awogbade, Paul Telfer, Mark Layton, Timothy Mant, Kobina Dufu, Athiwat Hutchaleelaha, Teri Koller, Donna Oksenberg, Mira Patel, Eleanor Ramos
Journal: Blood (2015)
NCO-07CASE REPORT: CARCINOMATOUS OPTIC NEUROPATHY
Authors: Kateryna Kurako, Rachana Gandhi, Efrain Salgado
Journal: Neuro-Oncology (2015)

38 years old female presented with progressive double vision followed by decreased visual acuity in left eye to almost 20/400 and later right eye. Her initial MRI B was unremarkable. LP showed opening pressure of 60, WBC 2, protein 144, normal glucose. Fundoscopic examination did not reveal any papilloedema. Considering her progressive vision loss and double vision, EVD was placed with resolution of her double vision and very mild improvement in her visual acuity. After 2 days, VP shunt was placed but her visual acuity got worse afterwards. MRV brain showed possible venous sinus thrombosis left transverse, sigmoid and internal jugular vein. At this point she also started having progressive numbness/tingling and weakness in her lower extremities. CT abdomen showed colon mass so she had colon biopsy showing poorly differentiated adenocarcinoma. At this point she was transferred to our facility for further evaluation. MRI T and L spine showed spinal root enhancement, repeat LP showed protein 1501, WBC 3 and normal glucose. EMG showed early intraspinal process at multiple levels affecting the lumbar and cervical spinal roots. Colon biopsy was repeated and confirmed poorly differentiated adenocarcinoma. Her CA 125 was 447 so ovarian carcinoma was suspected. CONCLUSION: Opthalmoplegia in our patient was probably from ICP secondary to carcinomatous meningitis. Even with progressive vision loss, she did not have papilledema so retrobulbar optic neuropathy was suspected which was thought to be secondary to paraneoplastic syndrome.
Evaluating Risk Factors and Outcomes For Clostridium Difficile Infection (CDI) In Stem Cell Transplant (SCT) Recipients
Authors: Nishi N Shah, Ajay K. Nooka, Jonathan L. Kaufman, Daniela Casbourne, Aocnp Aocnp, Donald Hutcherson, Rachael Maynard, Edmund K. Waller, Sagar Lonial, Amelia Langston
Journal: Blood (2013)
CRAd improve gene replication efficiency and cancer killing effect of E1-deleted adenovirus including killing gene
Authors: Seon Hui Shim, Seokwoo Park, Myungwhun Sung
Journal: Cancer Research (2008)

1389  To overcome low efficiency of gene therapy, we tried to combine Adenoviral vector including killing gene and CRAd (conditionally replicating adenovirus). CRAd show oncolytic action in cancer cells with abnormal Rb activity and help replication of E1-deleted Adenovirus including killing gene. We hypothesized that conventional E1-deleted adenovirus can replicate competently when co-transfected with a CRAd to selectively supply E1 in tumors by combining with CRAd and Adenovirus. As combining with CRAd and Adenovirus carrying TRAIL, we expected double effect that is the increase of killing gene expression in cancer cell and tumor killing effect. Additionally, we expected that this combination strategy could extend to multi-targeting cancer therapy.  First, to identify any increase of gene expression in conventional E1-deleted adenovirus, we tested combinational application with CRAd and Adeno-luciferase in head and neck cancer cell line and observed a big increase of luciferase activity by 10-50 times than transfection with Adeno-luciferase alone. Next, we investigated anti-cancer-effect of combination with Ad-TRAIL and CRAd, comparing with single transfection of Adeno -TRAIL and observed that combining CRAd and Adeno-TRAIL showed the increasing sub-G1 above 30 fold by PI staining than any single application in head and neck cancer cell lines.  When Co-transfected with CRAd, increasing expression of TRAIL by 3-5-fold than transduction with Adeno-TRAIL alone. These results represents that this combination with CRAd and Adenovirus increased killing gene transfer rate and enhanced its anti-tumor effect.  Next, we established head and neck cancer xenografts model in vivo and confirmed same result as in vitro. CRAd and Ad-TRAIL-treated mice showed regression of established tumors than CRAd or Adeno-TRAIL alone respectively  As on going experiment, we checked multi-targeting was also effective. We tried multi targeting gene therapy by combining with E1-deleted Adenovirus and CRAd. We combined Adeno-luciferase plus Adeno-LacZ plus Adeno-GFP and CRAd. We checked an activity of each gene. All of these reporter genes were expressed well without interruption among them. From these result, we expected that multi-targeting gene therapy could be possible. However, important things to do multi targeting gene therapy is finding suitable killing gene.
Competition authority will investigate price hikes of generic drugs
Authors: Nigel Hawkes
Journal: BMJ (2016)

Companies that made huge increases in the prices the NHS pays for out-of-patent medicines are facing an inquiry by the Competition and Markets Authority (CMA).

The CMA announced the investigation into “suspected unfair pricing by way of charging excessive prices in the supply of certain pharmaceutical products” without naming any of the companies being investigated. But the Times newspaper, which has run a series of investigative stories about generic drug pricing, reported that Concordia International, one of the companies featured in the stories, had confirmed that it was under investigation.1

Concordia, formerly known as AMCo,2 was formed by the private equity …